PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000197

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan

Identifieur interne : 000197 ( PascalFrancis/Corpus ); précédent : 000196; suivant : 000198

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan

Auteurs : Clyde Dapat ; Hiroki Kondo ; Isolde C. Dapat ; Tatiana Baranovich ; Yasushi Suzuki ; Yugo Shobugawa ; Kousuke Saito ; Reiko Saito ; Hiroshi Suzuki

Source :

Antiviral research [ 0166-3542 ] ; 2013.

RBID : Pascal:13-0363790

Descripteurs français

Pascal (Inist)
- Inhibiteur neuraminidase, Sensibilité, Profil, Grippe, Japon, Oséltamivir, Zanamivir, Péramivir, Antiviral, Pandémie, Concentration inhibitrice 50, Laninamivir.

English descriptors

KwdEn :
- Antiviral, Half maximal inhibitory concentration, Influenza, Japan, Laninamivir, Neuraminidase inhibitor, Oseltamivir, Peramivir, Profile, Sensitivity, Zanamivir.

Abstract

Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC₅₀) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC₅₀ values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC₅₀ values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC₅₀ values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0166-3542`
A02	`01`			`@0 ARSRDR`
A03		`1`		`@0 Antivir. res.`
A05				`@2 99`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan`
A11	`01`	`1`		`@1 DAPAT (Clyde)`
A11	`02`	`1`		`@1 KONDO (Hiroki)`
A11	`03`	`1`		`@1 DAPAT (Isolde C.)`
A11	`04`	`1`		`@1 BARANOVICH (Tatiana)`
A11	`05`	`1`		`@1 SUZUKI (Yasushi)`
A11	`06`	`1`		`@1 SHOBUGAWA (Yugo)`
A11	`07`	`1`		`@1 SAITO (Kousuke)`
A11	`08`	`1`		`@1 SAITO (Reiko)`
A11	`09`	`1`		`@1 SUZUKI (Hiroshi)`
A14	`01`			`@1 Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University @2 Niigata @3 JPN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 School of Nursing, Niigata Seiryo University @2 Niigata @3 JPN @Z 9 aut.`
A20				`@1 261-269`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18839 @5 354000501076070090`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/4`
A47	`01`	`1`		`@0 13-0363790`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral research`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC₅₀) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC₅₀ values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC₅₀ values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC₅₀ values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.
C02	`01`	`X`		`@0 002B02S05`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Inhibiteur neuraminidase @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Neuraminidase inhibitor @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Inhibidor neuraminidas @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Sensibilité @5 02`
C03	`02`	`X`	`ENG`	`@0 Sensitivity @5 02`
C03	`02`	`X`	`SPA`	`@0 Sensibilidad @5 02`
C03	`03`	`X`	`FRE`	`@0 Profil @5 03`
C03	`03`	`X`	`ENG`	`@0 Profile @5 03`
C03	`03`	`X`	`SPA`	`@0 Perfil @5 03`
C03	`04`	`X`	`FRE`	`@0 Grippe @5 04`
C03	`04`	`X`	`ENG`	`@0 Influenza @5 04`
C03	`04`	`X`	`SPA`	`@0 Gripe @5 04`
C03	`05`	`X`	`FRE`	`@0 Japon @2 NG @5 05`
C03	`05`	`X`	`ENG`	`@0 Japan @2 NG @5 05`
C03	`05`	`X`	`SPA`	`@0 Japón @2 NG @5 05`
C03	`06`	`X`	`FRE`	`@0 Oséltamivir @2 NK @2 FR @5 06`
C03	`06`	`X`	`ENG`	`@0 Oseltamivir @2 NK @2 FR @5 06`
C03	`06`	`X`	`SPA`	`@0 Oseltamivir @2 NK @2 FR @5 06`
C03	`07`	`X`	`FRE`	`@0 Zanamivir @2 NK @2 FR @5 07`
C03	`07`	`X`	`ENG`	`@0 Zanamivir @2 NK @2 FR @5 07`
C03	`07`	`X`	`SPA`	`@0 Zanamivir @2 NK @2 FR @5 07`
C03	`08`	`X`	`FRE`	`@0 Péramivir @2 FR @5 08`
C03	`08`	`X`	`ENG`	`@0 Peramivir @2 FR @5 08`
C03	`08`	`X`	`SPA`	`@0 Peramivir @2 FR @5 08`
C03	`09`	`X`	`FRE`	`@0 Antiviral @5 23`
C03	`09`	`X`	`ENG`	`@0 Antiviral @5 23`
C03	`09`	`X`	`SPA`	`@0 Antiviral @5 23`
C03	`10`	`X`	`FRE`	`@0 Pandémie @4 INC @5 86`
C03	`11`	`X`	`FRE`	`@0 Concentration inhibitrice 50 @4 CD @5 96`
C03	`11`	`X`	`ENG`	`@0 Half maximal inhibitory concentration @4 CD @5 96`
C03	`12`	`X`	`FRE`	`@0 Laninamivir @4 CD @5 97`
C03	`12`	`X`	`ENG`	`@0 Laninamivir @4 CD @5 97`
C03	`12`	`X`	`SPA`	`@0 Laninamivir @4 CD @5 97`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Asie @2 NG`
C07	`03`	`X`	`ENG`	`@0 Asia @2 NG`
C07	`03`	`X`	`SPA`	`@0 Asia @2 NG`
C07	`04`	`X`	`FRE`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`04`	`X`	`ENG`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`04`	`X`	`SPA`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`05`	`X`	`FRE`	`@0 Glycosidases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Glycosidases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Glycosidases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Glycosylases @2 FE`
C07	`06`	`X`	`ENG`	`@0 Glycosylases @2 FE`
C07	`06`	`X`	`SPA`	`@0 Glycosylases @2 FE`
C07	`07`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`07`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`07`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`08`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`08`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`08`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`09`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 38`
C07	`09`	`X`	`ENG`	`@0 Enzyme inhibitor @5 38`
C07	`09`	`X`	`SPA`	`@0 Inhibidor enzima @5 38`
C07	`10`	`X`	`FRE`	`@0 Dérivé du cyclopentane @5 39`
C07	`10`	`X`	`ENG`	`@0 Cyclopentane derivatives @5 39`
C07	`10`	`X`	`SPA`	`@0 Ciclopentano derivado @5 39`
N21				`@1 343`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 13-0363790 INIST
ET :	Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan
AU :	DAPAT (Clyde); KONDO (Hiroki); DAPAT (Isolde C.); BARANOVICH (Tatiana); SUZUKI (Yasushi); SHOBUGAWA (Yugo); SAITO (Kousuke); SAITO (Reiko); SUZUKI (Hiroshi)
AF :	Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University/Niigata/Japon (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); School of Nursing, Niigata Seiryo University/Niigata/Japon (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Antiviral research; ISSN 0166-3542; Coden ARSRDR; Royaume-Uni; Da. 2013; Vol. 99; No. 3; Pp. 261-269; Bibl. 1 p.1/4
LA :	Anglais
EA :	Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC₅₀) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC₅₀ values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC₅₀ values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC₅₀ values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.
CC :	002B02S05; 002B05C02C
FD :	Inhibiteur neuraminidase; Sensibilité; Profil; Grippe; Japon; Oséltamivir; Zanamivir; Péramivir; Antiviral; Pandémie; Concentration inhibitrice 50; Laninamivir
FG :	Virose; Infection; Asie; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Inhibiteur enzyme; Dérivé du cyclopentane
ED :	Neuraminidase inhibitor; Sensitivity; Profile; Influenza; Japan; Oseltamivir; Zanamivir; Peramivir; Antiviral; Half maximal inhibitory concentration; Laninamivir
EG :	Viral disease; Infection; Asia; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Enzyme inhibitor; Cyclopentane derivatives
SD :	Inhibidor neuraminidas; Sensibilidad; Perfil; Gripe; Japón; Oseltamivir; Zanamivir; Peramivir; Antiviral; Laninamivir
LO :	INIST-18839.354000501076070090
ID :	13-0363790

Links to Exploration step

Pascal:13-0363790

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan</title>
<author><name sortKey="Dapat, Clyde" sort="Dapat, Clyde" uniqKey="Dapat C" first="Clyde" last="Dapat">Clyde Dapat</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kondo, Hiroki" sort="Kondo, Hiroki" uniqKey="Kondo H" first="Hiroki" last="Kondo">Hiroki Kondo</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dapat, Isolde C" sort="Dapat, Isolde C" uniqKey="Dapat I" first="Isolde C." last="Dapat">Isolde C. Dapat</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baranovich, Tatiana" sort="Baranovich, Tatiana" uniqKey="Baranovich T" first="Tatiana" last="Baranovich">Tatiana Baranovich</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suzuki, Yasushi" sort="Suzuki, Yasushi" uniqKey="Suzuki Y" first="Yasushi" last="Suzuki">Yasushi Suzuki</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shobugawa, Yugo" sort="Shobugawa, Yugo" uniqKey="Shobugawa Y" first="Yugo" last="Shobugawa">Yugo Shobugawa</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saito, Kousuke" sort="Saito, Kousuke" uniqKey="Saito K" first="Kousuke" last="Saito">Kousuke Saito</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saito, Reiko" sort="Saito, Reiko" uniqKey="Saito R" first="Reiko" last="Saito">Reiko Saito</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suzuki, Hiroshi" sort="Suzuki, Hiroshi" uniqKey="Suzuki H" first="Hiroshi" last="Suzuki">Hiroshi Suzuki</name>
<affiliation><inist:fA14 i1="02"><s1>School of Nursing, Niigata Seiryo University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0363790</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0363790 INIST</idno>
<idno type="RBID">Pascal:13-0363790</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000197</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan</title>
<author><name sortKey="Dapat, Clyde" sort="Dapat, Clyde" uniqKey="Dapat C" first="Clyde" last="Dapat">Clyde Dapat</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kondo, Hiroki" sort="Kondo, Hiroki" uniqKey="Kondo H" first="Hiroki" last="Kondo">Hiroki Kondo</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dapat, Isolde C" sort="Dapat, Isolde C" uniqKey="Dapat I" first="Isolde C." last="Dapat">Isolde C. Dapat</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baranovich, Tatiana" sort="Baranovich, Tatiana" uniqKey="Baranovich T" first="Tatiana" last="Baranovich">Tatiana Baranovich</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suzuki, Yasushi" sort="Suzuki, Yasushi" uniqKey="Suzuki Y" first="Yasushi" last="Suzuki">Yasushi Suzuki</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shobugawa, Yugo" sort="Shobugawa, Yugo" uniqKey="Shobugawa Y" first="Yugo" last="Shobugawa">Yugo Shobugawa</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saito, Kousuke" sort="Saito, Kousuke" uniqKey="Saito K" first="Kousuke" last="Saito">Kousuke Saito</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saito, Reiko" sort="Saito, Reiko" uniqKey="Saito R" first="Reiko" last="Saito">Reiko Saito</name>
<affiliation><inist:fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Suzuki, Hiroshi" sort="Suzuki, Hiroshi" uniqKey="Suzuki H" first="Hiroshi" last="Suzuki">Hiroshi Suzuki</name>
<affiliation><inist:fA14 i1="02"><s1>School of Nursing, Niigata Seiryo University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Half maximal inhibitory concentration</term>
<term>Influenza</term>
<term>Japan</term>
<term>Laninamivir</term>
<term>Neuraminidase inhibitor</term>
<term>Oseltamivir</term>
<term>Peramivir</term>
<term>Profile</term>
<term>Sensitivity</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Inhibiteur neuraminidase</term>
<term>Sensibilité</term>
<term>Profil</term>
<term>Grippe</term>
<term>Japon</term>
<term>Oséltamivir</term>
<term>Zanamivir</term>
<term>Péramivir</term>
<term>Antiviral</term>
<term>Pandémie</term>
<term>Concentration inhibitrice 50</term>
<term>Laninamivir</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC<sub>50</sub>
) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC<sub>50</sub>
 values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC<sub>50</sub>
 values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC<sub>50</sub>
 values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0>
</fA01>
<fA02 i1="01"><s0>ARSRDR</s0>
</fA02>
<fA03 i2="1"><s0>Antivir. res.</s0>
</fA03>
<fA05><s2>99</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DAPAT (Clyde)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KONDO (Hiroki)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DAPAT (Isolde C.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BARANOVICH (Tatiana)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SUZUKI (Yasushi)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SHOBUGAWA (Yugo)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SAITO (Kousuke)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SAITO (Reiko)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SUZUKI (Hiroshi)</s1>
</fA11>
<fA14 i1="01"><s1>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>School of Nursing, Niigata Seiryo University</s1>
<s2>Niigata</s2>
<s3>JPN</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>261-269</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18839</s2>
<s5>354000501076070090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0363790</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral research</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC<sub>50</sub>
) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC<sub>50</sub>
 values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC<sub>50</sub>
 values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC<sub>50</sub>
 values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Inhibiteur neuraminidase</s0>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Neuraminidase inhibitor</s0>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Inhibidor neuraminidas</s0>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Sensibilité</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Sensitivity</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sensibilidad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Profil</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Profile</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Perfil</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Grippe</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Influenza</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Gripe</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Japon</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Japan</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Japón</s0>
<s2>NG</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Oséltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Oseltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Oseltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Zanamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Zanamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Zanamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Péramivir</s0>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Peramivir</s0>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Peramivir</s0>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pandémie</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Concentration inhibitrice 50</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Half maximal inhibitory concentration</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Laninamivir</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Laninamivir</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Laninamivir</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Asie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>38</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Dérivé du cyclopentane</s0>
<s5>39</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Cyclopentane derivatives</s0>
<s5>39</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Ciclopentano derivado</s0>
<s5>39</s5>
</fC07>
<fN21><s1>343</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 13-0363790 INIST</NO>
<ET>Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan</ET>
<AU>DAPAT (Clyde); KONDO (Hiroki); DAPAT (Isolde C.); BARANOVICH (Tatiana); SUZUKI (Yasushi); SHOBUGAWA (Yugo); SAITO (Kousuke); SAITO (Reiko); SUZUKI (Hiroshi)</AU>
<AF>Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University/Niigata/Japon (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); School of Nursing, Niigata Seiryo University/Niigata/Japon (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Antiviral research; ISSN 0166-3542; Coden ARSRDR; Royaume-Uni; Da. 2013; Vol. 99; No. 3; Pp. 261-269; Bibl. 1 p.1/4</SO>
<LA>Anglais</LA>
<EA>Two new influenza virus neuraminidase inhibitors (NAIs), peramivir and laninamivir, were approved in 2010 which resulted to four NAIs that were used during the 2010-2011 influenza season in Japan. This study aims to monitor the susceptibility of influenza virus isolates in 2009-2010 and 2010-2011 influenza seasons in Japan to the four NAIs using the fluorescence-based 50% inhibitory concentration (IC<sub>50</sub>
) method. Outliers were identified using box-and-whisker plot analysis and full NA gene sequencing was performed to determine the mutations that are associated with reduction of susceptibility to NAIs. A total of 117 influenza A(H1N1)pdm09, 59 A(H3N2), and 18 type B viruses were tested before NAI treatment and eight A(H1N1)pdm09 and 1 type B viruses were examined from patients after NAI treatment in the two seasons. NA inhibition assay showed type A influenza viruses were more susceptible to NAIs than type B viruses. The peramivir and laninamivir IC<sub>50</sub>
 values of both type A and B viruses were significantly lower than the oseltamivir and zanamivir IC<sub>50</sub>
 values. Among influenza A(H1N1)pdm09 viruses, the prevalence of H274Y viruses increased from 0% in the 2009-2010 season to 3% in the 2010-2011 season. These H274Y viruses were resistant to oseltamivir and peramivir with 200-300 fold increase in IC<sub>50</sub>
 values but remained sensitive to zanamivir and laninamivir. Other mutations in NA, such as I222T and M241I were identified among the outliers. Among influenza A(H3N2) viruses, two outliers were identified with D151G and T148I mutations, which exhibited a reduction in susceptibility to oseltamivir and zanamivir, respectively. Among type B viruses, no outliers were identified to the four NAIs. For paired samples that were collected before and after drug treatment, three (3/11; 27.3%) H274Y viruses were identified among A(H1N1)pdm09 viruses after oseltamivir treatment but no outliers were found in the laninamivir-treatment group (n = 3). Despite widespread use of NAIs in Japan, the prevalence of NAI-resistant influenza viruses is still low.</EA>
<CC>002B02S05; 002B05C02C</CC>
<FD>Inhibiteur neuraminidase; Sensibilité; Profil; Grippe; Japon; Oséltamivir; Zanamivir; Péramivir; Antiviral; Pandémie; Concentration inhibitrice 50; Laninamivir</FD>
<FG>Virose; Infection; Asie; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Inhibiteur enzyme; Dérivé du cyclopentane</FG>
<ED>Neuraminidase inhibitor; Sensitivity; Profile; Influenza; Japan; Oseltamivir; Zanamivir; Peramivir; Antiviral; Half maximal inhibitory concentration; Laninamivir</ED>
<EG>Viral disease; Infection; Asia; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Enzyme inhibitor; Cyclopentane derivatives</EG>
<SD>Inhibidor neuraminidas; Sensibilidad; Perfil; Gripe; Japón; Oseltamivir; Zanamivir; Peramivir; Antiviral; Laninamivir</SD>
<LO>INIST-18839.354000501076070090</LO>
<ID>13-0363790</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000197 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000197 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0363790
   |texte=   Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri